The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function

Prostaglandins and Other Lipid Mediators

Volumn 97, Issue 1-2, 2012, Pages 29-35

  Yan, Yi Xuan ^a   Li, Wei Zhong ^a   Huang, Yan Qing ^a   Liao, Wen Xiao ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Celecoxib; Cyclooxygenase 2; KB VCR cell; Multidrug resistant; P glycoprotein

Indexed keywords

CELECOXIB; GLYCOPROTEIN P; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; MOUTH CANCER; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KB CELLS; MOUTH NEOPLASMS; P-GLYCOPROTEIN; PYRAZOLES; SULFONAMIDES; VINCRISTINE;

EID: 84855765648     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2011.07.007     Document Type: Article

References (42)

1. C.H. Shiboski, B.L. Schmidt, and R.C. Jordan Tongue and tonsil carcinoma: increasing trends in the US population ages 20-44 years Cancer 103 9 2005 1843 1849 (Pubitemid 40563256)
2. M.G. Biazevic, J.L. Antunes, and J. Togni Survival and quality of life of patients with oral and oropharyngeal cancer at 1-year follow-up of tumor resection J Appl Oral Sci 18 3 2010 279 284
3. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, and M.M. Gottesman Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 39 1991 361 398
4. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2 1 2002 48 58 (Pubitemid 37328807)
5. J.A. Endicott, and V. Ling The biochemistry of P-glycoprotein-mediated multidrug resistance Annu Rev Biochem 58 1989 137 171 (Pubitemid 19172967)
6. M.M. Gottesman, and V. Ling The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research FEBS Lett 580 4 2006 998 1009 (Pubitemid 43185280)
7. F. Staud, M. Ceckova, S. Micuda, and P. Pavek Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics Methods Mol Biol 596 2010 199 222
8. D.S. Miller, B. Bauer, and A.M. Hartz Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy Pharmacol Rev 60 2 2008 196 209 (Pubitemid 351962009)
9. G. Bleiber, M. May, and C. Suarez MDR1 genetic polymorphism does not modify either cell permissiveness or disease progression before treatment J Infect Dis 189 4 2004 583 586 (Pubitemid 38270909)
10. B. Chen, F. Jing, X.L. Lu, P.P. Wang, Y.P. Liu, and S.B. Wang Effect of PKC inhibitor on P-gp expression and drug-resistance in MGC-803 cells Chin J Cancer 23 4 2004 396 400
11. D.L. Gregory, F. Tito, and E.B. Susan The role of ABC transporters in clinical practice Oncologist 8 5 2003 411 424
12. J.B. Méric, S. Rottey, and K. Olaussen Cyclooxygenase-2 as a target for anticancer drug development Crit Rev Oncol Hematol 59 1 2006 51 64 (Pubitemid 43903278)
13. J. Fortuny, C.C. Johnson, and K. Bohlke Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers Clin Gastroenterol Hepatol 5 10 2007 1154 1159
14. D.J. de Groot, E.G. de Vries, H.J. Groen, and S. de Jong Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic Crit Rev Oncol Hematol 61 1 2007 52 69 (Pubitemid 44880148)
15. K. Sappayatosok, Y. Maneerat, and S. Swasdison Expression of pro-inflammatory protein, iNOS, VEGF and COX-2 in oral squamous cell carcinoma (OSCC), relationship with angiogenesis and their clinico-pathological correlation Med Oral Patol Oral Cir Bucal 14 7 2009 e319 e324
16. M.R. Raspollini, G. Amunni, A. Villanucci, V. Boddi, and G.L. Taddei Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival Int J Gynecol Cancer 15 2 2005 255 260 (Pubitemid 40396961)
17. L. Yu, W.K. Wu, and Z.J. Li Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl) -1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity Mol Pharmacol 75 6 2009 1364 1373
18. S.H. Kim, S.H. Kim, Y.C. Song, and Y.S. Song Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase Ann N Y Acad Sci 1171 1 2009 635 641
19. W.Z. Li, Q. Huo, X.Y. Wang, and F. Xu Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression Prostaglandins Other Lipid Mediat 93 3-4 2010 113 139
20. W.Z. Li, X.Y. Wang, Z.G. Li, J.H. Zhang, and Y.Q. Ding Celecoxib enhances the inhibitory effect of Tca8113 cells in human tongue squamous cell carcinoma in vivo and vitro J Oral Pathol Med 39 7 2010 579 584
21. A.R. Bassiouny, A. Zaky, and H.M. Neenaa Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients Ann Hepatol 9 4 2010 410 418
22. S. Huang, and F.A. Sinicrope Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells Autophagy 6 2 2010 256 269
23. M. Seiz, P. Kohlhof, and M.A. Brockmann First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity Anticancer Res 29 8 2009 3261 3267
24. A.M. Lipskar, R.D. Glick, and J. Huang Cyclooxygenase 2 mediates the antiangiogenic effect of rapamycin in Ewing sarcoma J Pediatr Surg 44 6 2009 1139 1146 discussion 1146-7
25. A. Zrieki, R. Farinotti, and M. Buyse Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo Eur J Pharmacol 636 1-3 2010 189 197
26. M.C. Zatelli, A. Luchin, and D. Piccin Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism J Clin Endocrinol Metab 90 10 2005 5754 5760 (Pubitemid 41415487)
27. Z.J. Jin Addition in drug combination Zhongguo Yaoli Xuebao 1 2 1980 70 76 [in Chinese] (Pubitemid 11178371)
28. K.H. Shain, and W.S. Dalton Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR Mol Cancer Ther 1 1 2001 69 78
29. F. Leonessa, and R. Clarke ATP binding cassette transporters and drug resistance in breast cancer Endocr Relat Cancer 10 1 2003 43 73 (Pubitemid 36457239)
30. G. Nardone, A. Rocco, and D. Vaira Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H. pylori-related gastric carcinogenesis J Pathol 202 3 2004 305 312 (Pubitemid 38325239)
31. B. Miller, V.A. Patel, and A. Sorokin Cyclooxygenase-2 rescues rat mesangial cells from apoptosis induced by adriamycin via upregulation of multidrug resistance protein 1 (P-glycoprotein) J Am Soc Nephrol 17 4 2006 977 985
32. J.Y. Lee, S. Tanabe, and H. Shimohira Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma Res Vet Sci 83 2 2007 210 216 (Pubitemid 46971710)
33. O. Fantappi, M. Solazzo, N. Lasagna, F. Platini, L. Tessitore, and R. Mazzanti P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines Cancer Res 67 10 2007 4915 4923 (Pubitemid 46910199)
34. W.M. Awara, A.E. El Sisi, M.E. El Sayad, and A.E. Goda The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin? Pharmacol Res 50 5 2004 487 498 (Pubitemid 39349050)
35. M.C. Zatelli, A. Luchin, and F. Tagliati Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression Endocr Relat Cancer 14 4 2007 1029 1038 (Pubitemid 351252434)
36. K.M. Arunasree, K.R. Roy, K. Anilkumar, A. Aparna, G.V. Reddy, and P. Reddanna Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1 Leuk Res 32 6 2008 855 864
37. A. Zrieki, R. Farinotti, and M. Buyse Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line Pharm Res 25 9 2008 1991 2001
38. N. Muller, M. Riedel, and C. Scheppach Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia Am J Psychiatry 159 6 2002 1029 1034 (Pubitemid 34586950)
39. J. Weiss, S.M. Dormann, M. Martin-Facklam, C.J. Kerpen, N. Ketabi-Kiyanvash, and W.E. Haefeli Inhibition of P-glycoprotein by newer antidepressants J Pharmacol Exp Ther 305 1 2003 197 204 (Pubitemid 36373851)
40. E.F. de Vries, J. Doorduin, N.A. Vellinga, A. van Waarde, R.A. Dierckx, and H.C. Klein Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study Nucl Med Biol 35 4 2008 459 466
41. I. Tegeder, J. Pfeilschifter, and G. Geisslinger Cyclooxygenase- independent actions of cyclooxygenase inhibitors FASEB J 15 12 2001 2057 2072 (Pubitemid 32927924)
42. C. Chen, H.L. Shen, J. Yang, Q.Y. Chen, and W.L. Xu Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib J Cancer Res Clin Oncol 137 1 2011 9 17